Press Releases
-
Sep 17 ,2021
- Conference Dates: September 20th-23rd - BETHESDA, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and...
Sep 09 ,2021BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company’s proprietary Structurally Targeted Allosteric Regulators (STARs) for GM1...
Sep 08 ,2021GT-02287and GT-02329 compounds display positive effects on GCase activityand related parameters--- Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and decrease of glucosylceramide andα-synuclein-p129 levels--- Comprehensive study results to be presented at Michael J. Fox Foundation’s upcomingInnovating from Drug Discovery to the Clinic: Novel Approaches to PD Therapeutic Development webinar--- IND-initiating study planned for Q4’21 BETHESDA,...